Now, a research team from University Hospitals, Case Western Reserve University, and the Louis Stokes Cleveland VA Medical Center has challenged this long-held dogma in the field. They tested whether brains already badly afflicted with advanced AD could recover.
MannKind (Nasdaq:MNKD) announced today that the FDA approved its Furoscix (furosemide) on-body infusor for pediatric patients.
A new method could enable users to design portable medical devices, like a splint, that can be rapidly converted from flat panels to a 3D object without any tools.
Edwards Lifesciences (NYSE: EW)+
has won FDA approval for its Sapien M3 mitral valve replacement system for treating mitral regurgitation (MR).
Shape Memory Medical’s IMPEDE embolisation plug range has received CE mark as a Class III device under the European Union’s Medical Device Regulation (EU MDR).
A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver disease called primary sclerosing cholangitis. Researchers learned that an anti-inflammatory and anti-fibrotic monoclonal antibody known as nebokitug was safe and showed potential efficacy in patients with PSC.
A new study in the lab of Jason Stein, Ph.D., modeled brain development in a dish to identify cells and genes that influence infant brain growth, a trait associated with autism.
Diabeloop announced today that its DBLG2 algorithm for automated insulin delivery has received FDA 510(k) clearanc
Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.
Abbott (NYSE: ABT)+
announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.